ID: h-28f5f4a34b
Hypothesis
Complement C1q/C3 Inhibition to Prevent Synaptodendritis in Alzheimer's Disease
Blocking early complement activation prevents microglia-mediated excessive synapse loss before and during amyloid deposition.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Blocking early complement activation prevents microglia-mediated excessive synapse loss before and during amyloid deposition. C1q localized to synapses in early AD correlates with cognitive decline; C3 knockout or CR3 deficiency protects synapses in 5xFAD mice. Annexon's ANX005 anti-C1q antibody has human CNS target engagement experience from Huntington's disease trials.
🧬 Mechanism
No curated mechanism pathway recorded for this hypothesis.
⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
C1q localizes to synapses in early AD; C3 deposition correlates with memory loss
Contradicts
C1q/C3 inhibition may impair necessary synaptic pruning during development
Contradicts
Timing critical; complement has dual roles in development vs. adult neurodegeneration
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — C1Q
No curated PDB or AlphaFold mapping for C1Q yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for C1Q.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.2%
Volatility
Low
0.0022
Events (7d)
3
Price History
▼15.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with early-stage Alzheimer's disease (prodromal AD or MCI due to AD, confirmed by amyloid PET and CSF biomarkers) receive monthly intravenous ANX005 (anti-C1q) at 20 mg/kg for 12 months, T | CSF neurogranin concentration will be 30% lower in the treatment arm compared to placebo at month 18 | — no observation — | pending | 0.65 |
| IF 5xFAD mice receive intraperitoneal anti-C1q antibody (10 mg/kg, twice weekly) starting at 2 months of age and continuing for 6 months, THEN synaptic complement C3 deposition on hippocampal CA1 syna | Synaptic C3 fractional area on hippocampal CA1 neurons will be reduced by ≥50% in anti-C1q treated mice vs. control | — no observation — | pending | 0.78 |
🔮 Falsifiable Predictions (2)
pendingconf 78%
IF 5xFAD mice receive intraperitoneal anti-C1q antibody (10 mg/kg, twice weekly) starting at 2 months of age and continuing for 6 months, THEN synaptic complement C3 deposition on hippocampal CA1 synapses will be reduced by at least 50% compared to isotype-control treated 5xFAD mice.
Predicted outcome: Synaptic C3 fractional area on hippocampal CA1 neurons will be reduced by ≥50% in anti-C1q treated mice vs. control
Falsification: Synaptic complement C3 deposition shows no significant reduction or increases in treated mice; electrophysiological measures (mEPSC frequency/amplitude) remain equivalent between groups
pendingconf 65%
IF patients with early-stage Alzheimer's disease (prodromal AD or MCI due to AD, confirmed by amyloid PET and CSF biomarkers) receive monthly intravenous ANX005 (anti-C1q) at 20 mg/kg for 12 months, THEN their CSF synaptic biomarker neurogranin will decrease by at least 30% relative to placebo, indi
Predicted outcome: CSF neurogranin concentration will be 30% lower in the treatment arm compared to placebo at month 18
Falsification: CSF neurogranin levels show no significant difference or increase in the treatment arm vs. placebo; synapse loss as measured by synaptic density PET remains equivalent between groups
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.